Beyond Air, Inc. (XAIR) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Beyond Air, Inc. (XAIR) closed at USD 2.10 on 2026-10-14, a change of -95 % over the past year, with a market capitalization of USD 2.18M.

Beyond Air, Inc. recent closing prices

DateClose (USD)
2026-10-142.10
2026-10-132.19
2026-10-122.31
2026-10-092.25
2026-10-082.31
2026-10-072.54
2026-10-062.55

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Beyond Air, Inc. key figures

Previous close
USD 2.10 (2026-10-14)
1-year change
-95 %
Market cap
USD 2.18M
Enterprise value
USD 16.74M
P/E ratio (trailing)
-0.03
P/E ratio (forward)
-1.33
EPS (trailing)
-64.40
EPS (forward)
-1.66
PEG ratio
n/a
Price to book
0.82
Revenue growth
0.5 %
Earnings growth
n/a
Dividend per share (trailing)
0.00
Short ratio
0.13
Employees
54
Analyst consensus (third-party)
strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Beyond Air, Inc.

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Beyond Air, Inc. and compare it with other stocks.

Analyze XAIRAll Other US Stocks stocks

Stock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Beyond Air, Inc. shares.